James Hinrichs Appointed to Board of Directors and Chairman of the Audit Committee of Outset Medical

Outset Medical CEO, Leslie Trigg said, “We are thrilled to have James Hinrichs join our Board of Directors. With a 30-year track record of both private and public company success, his governance and financial operations experience in high-growth environments will be invaluable to Outset.”

James Hinrichs has held the role of Chief Financial Officer at multiple companies including Alere Inc. until its sale to Abbott Labs, and CareFusion Corporation until its sale to Becton Dickinson. James Hinrichs also currently serves as a director of Orthofix Inc., Integer Holdings, Acutus Medical and Cibus. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.

“Outset is poised for significant growth, and I’m incredibly excited to join their board,” said Mr. Hinrichs. “The expanded commercialization of Tablo will give providers much-needed innovation to reduce the cost and complexity of delivering dialysis.”

Dialysis is delivered to more than 550,000 U.S. patients several times per week to remove waste products and excess fluid from patients with kidney failure. Although more than 85 million dialysis treatments take place in the United States each year at an estimated annual cost of ~$75 billion, little meaningful technology or service model innovation has been introduced in decades.

Outset Medical’s Tablo was designed as an enterprise solution to reduce the cost and complexity of dialysis while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated into a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of use environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen make Tablo easy to learn and use for healthcare professionals and patients alike.


Other executives on the move can be found here.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.